CN114555131A - 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法 - Google Patents

用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法 Download PDF

Info

Publication number
CN114555131A
CN114555131A CN202080070370.6A CN202080070370A CN114555131A CN 114555131 A CN114555131 A CN 114555131A CN 202080070370 A CN202080070370 A CN 202080070370A CN 114555131 A CN114555131 A CN 114555131A
Authority
CN
China
Prior art keywords
compound
independently
mannose
macrophages
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070370.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·拉尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of CN114555131A publication Critical patent/CN114555131A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080070370.6A 2019-08-19 2020-08-19 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法 Pending CN114555131A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888727P 2019-08-19 2019-08-19
US62/888,727 2019-08-19
PCT/US2020/047036 WO2021034953A1 (en) 2019-08-19 2020-08-19 Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells

Publications (1)

Publication Number Publication Date
CN114555131A true CN114555131A (zh) 2022-05-27

Family

ID=74647058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070370.6A Pending CN114555131A (zh) 2019-08-19 2020-08-19 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法

Country Status (7)

Country Link
US (1) US20210052639A1 (https=)
EP (1) EP4017546A4 (https=)
JP (1) JP2022544836A (https=)
CN (1) CN114555131A (https=)
CA (1) CA3151519A1 (https=)
IL (1) IL290593A (https=)
WO (1) WO2021034953A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2025096664A1 (en) * 2023-10-31 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional cd206-binding molecules and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764529A (zh) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US20160206763A1 (en) * 2015-01-21 2016-07-21 Navidea Biopharmaceuticals, Inc. Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20180099048A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
AU2006204045B2 (en) * 2005-01-05 2010-10-14 Board Of Regents, The University Of Texas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
JP5320569B2 (ja) * 2008-06-28 2013-10-23 公益財団法人神奈川科学技術アカデミー 高分子ミセル及びそれを有効成分として含有する固形がんの診断又は治療剤
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764529A (zh) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US20160206763A1 (en) * 2015-01-21 2016-07-21 Navidea Biopharmaceuticals, Inc. Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20180099048A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same

Also Published As

Publication number Publication date
EP4017546A4 (en) 2023-09-27
JP2022544836A (ja) 2022-10-21
WO2021034953A1 (en) 2021-02-25
EP4017546A1 (en) 2022-06-29
IL290593A (en) 2022-04-01
US20210052639A1 (en) 2021-02-25
CA3151519A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
US10143699B2 (en) Compositions and methods for inhibiting arginase activity
US9034862B2 (en) Compositions and methods for the treatment of cancer
JP7665206B2 (ja) マクロファージの表現型を改変するための組成物および方法
CN114555131A (zh) 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法
SA516371814B1 (ar) جسيمات نانوية علاجية تشمل عامل علاجى وطرق صنعها وإستخدامها
JP7599727B2 (ja) マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット
JP2022501394A (ja) Ｍｄｍ２阻害剤の医薬組成物、並びに疾患を予防及び／又は治療するためのその使用
US20100173865A1 (en) Anti-Cancer Agent-Hyaluronic Acid Conjugate Compositions and Methods
US11833170B2 (en) Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
CN111542310A (zh) 包含担载有抗癌剂的纳米结构体作为有效成分的肝癌治疗用药学组合物
CN110958998B (zh) 毛兰素衍生物和使用毛兰素衍生物的方法
US10383943B2 (en) Compositions and related methods for the treatment of cancer
US20240024491A1 (en) Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
US20240294564A1 (en) Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
JP2025040508A (ja) 代謝性骨疾患治療剤およびそれを含む医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination